StockNews.com started coverage on shares of Gilead Sciences ( NASDAQ:GILD – Free Report ) in a research report released on Thursday. The firm issued a strong-buy rating on the biopharmaceutical company's stock. A number of other research analysts have also weighed in on the stock. BMO Capital Markets dropped their price target on shares of Gilead Sciences from $100.00 to $95.00 in a research report on Tuesday, July 18th. Barclays dropped their price target on shares of Gilead Sciences from $81.

https://www.dailypolitical.com/2023/08/20/stocknews-com-begins-coverage-on-gilead-sciences-nasdaqgild.html

#dailypolitical